Severe Thrombocytopenia Diagnosis and Management

Key Clinical Considerations

The American Society of Hematology recommends immediate hospitalization for patients with severe thrombocytopenia (platelet count <20,000/μL) and bleeding manifestations, due to the high risk of serious bleeding 1
Patients with severe thrombocytopenia should be evaluated for life-threatening causes, including immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), drug-induced thrombocytopenia, and heparin-induced thrombocytopenia (HIT) 1

Immune thrombocytopenic purpura (ITP) is the most likely diagnosis in a young adult with isolated severe thrombocytopenia and purpura, characterized by mucocutaneous bleeding and normal-sized or slightly larger platelets with normal RBC/WBC morphology 1, 2
Drug-induced thrombocytopenia should be considered in patients with recent exposure to common culprits, such as quinidine, heparin, sulfonamides, sulfonylureas, dipyridamole, and salicylates 1
Thrombotic thrombocytopenic purpura (TTP) requires urgent plasma exchange if suspected, and is characterized by thrombocytopenia, microangiopathic hemolytic anemia, neurologic changes, renal dysfunction, and fever 3, 4, 5

A complete blood count with peripheral blood smear is essential to confirm true thrombocytopenia vs. pseudothrombocytopenia, and to examine red blood cell morphology for schistocytes (suggests TTP, DIC, or other microangiopathy) 1, 2, 6
Coagulation studies, including PT/INR and aPTT, should be performed to exclude DIC or coagulation factor deficiencies 7
A comprehensive metabolic panel, including renal function and liver function tests, should be performed to exclude underlying systemic disease 1, 4

The American Society of Hematology recommends against platelet-associated IgG assay, platelet antigen-specific antibody assay, serum complement levels, and platelet survival studies, as they are unnecessary and do not change management 1
High-dose glucocorticoids and intravenous immunoglobulin (IVIg) are initial treatment options for ITP, with combination therapy reserved for life-threatening bleeding 1, 8, 2
Platelet transfusion should be reserved for active life-threatening hemorrhage, as prophylactic transfusion provides no benefit and risks alloimmunization 2, 7